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 Introduction  
 Quality of life (QoL) measurement has gained increas-
ing attention in medicine, and is implemented more and 
more in clinical trials and health care policy. Although 
initially developed as an assessment of treatment effec-
tiveness in chronically ill patients with somatic disorders, 
QoL measurements are now used in patients with mental 
disorders, both outpatients and inpatients, during acute 
and continuation/maintenance treatment. 
 In a previous review, the authors concluded that QoL 
was an active area of research in the field of depressive 
disorders; outcome measures were no longer limited to 
symptom scales, and further research could improve 
treatment outcomes by developing strategies that went 
beyond symptom resolution. Furthermore, a concern was 
raised about the lack of consensus on the concept and 
measurement of QoL  [1] . Is this interest still present? Are 
these concerns still true? To answer these questions, the 
authors have analysed the use of QoL measurement in 
recent antidepressant trials. This analysis is preceded by 
a brief history of QoL measurement and the different un-
derlying concepts. 
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 Abstract 
 Background: Quality of life (QoL) measurement in medicine 
has gone a long way. It has gained popularity as a more hu-
manitarian outcome measurement. In this paper, a review is 
given of its historical backgrounds with a special focus on 
the use of QoL assessment in psychiatry. Different theoreti-
cal concepts are discussed. A closer look is taken at the use 
of QoL measurements in antidepressant trials. Methods: An 
analysis was performed on the use of QoL measurement in 
recent antidepressant trials of duloxetine and escitalopram. 
Results: QoL measurement was found to have abandoned 
its initial purposes, and to have been used without any theo-
retical framework. Conclusions: Although frequently used 
in antidepressant trials, the analysis and reporting of results 
is virtually non-existent. It remains unclear if QoL measure-
ment, as currently used, gives any information that is not al-
ready captured by more formal depression rating scales. The 
question then remains whether QoL measurement in anti-
depressant trials has any added value and, if so, whether this 
is just a story of missed opportunities. 
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 Quality of Life: A Brief History  
 In a Medline search for QoL, 76,502 papers were found 
over the last 45 years with a marked increase starting in 
the late 1970s ( fig. 1 ). As shown in more refined biblio-
metric searches for QoL and different mental disorders, 
this growing interest also applies to psychiatry in par-
ticular ( fig. 2 ). 
 Medical interest in QoL stems from a concern for the 
quality of health care processes and a desire to better 
monitor the individual outcome of medical care  [2] . QoL 
assessment tried to complement the traditional medical 
emphasis on survival time or quantity of life, in which 
basic human needs were sometimes neglected  [3] . It has 
offered a way of monitoring the long-term care of chron-
ically ill people (for whom cure is not an option), and 
places more importance on the patient’s perception of 
their health status. This concept was first applied in med-
ical practices such as oncology and cardiology: function-
ing, well-being, or life satisfaction became outcome mea-
sures of cancer treatment and treatment with antihyper-
tensive medications  [4, 5] . 
 Different arguments for the growing interest in QoL 
measurement in psychiatry are found. Firstly, after the 
early enthusiasm resulting from deinstitutionalization 
and psychotropic drugs, it became clear that just being 
out of the hospital or getting medical treatment wasn’t a 
good enough outcome for most patients with severe men-
tal illness  [6] . Traditional outcome measures (hospital
recidivism, symptom reduction) overemphasized ther-
apeutic goals. Other important needs and concerns of
patients were therefore neglected, e.g. material living 
conditions, negative physical, psychological, and social 
side effects. Strictly defined medical outcome measures 
for severe mental disorders were at risk of reflecting the 
well-known medical aphorism, ‘the surgery was a suc-
cess, but the patient died’, and QoL research introduced 
a more humanitarian concern  [7, 8] . 
 Secondly, QoL scales were also introduced by pharma-
ceutical companies as a means of measuring the overall 
and differential impact of antidepressant treatment. Se-
lective serotonin reuptake inhibitors were introduced in 
the mid-1980s. These compounds were no more effective 
in the treatment of severe depression, but were believed 
to have fewer side effects, to be safer when overdosed, and 
thereby to be more suitable for the treatment of primary 
care depressions than the older tricyclic antidepressants. 
It was hoped that QoL scales could better capture this 
beneficial overall impact of treatment  [9] : QoL as a kind 
of compact risk-benefit analysis. 
 Thirdly, QoL assessments made it possible to compare 
the impact of different disorders both on the individual 
and societal levels. An example of this latter phenomenon 
was the seminal Medical Outcomes Study of Wells et al. 
 [10] , in which the functioning and well-being of patients 
with depression were described, relative to patients with 
chronic medical conditions or no chronic conditions. 
When compared to patients with no chronic conditions, 
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 Fig. 1. Publication trends regarding QoL (1960–2005). Medline 
search: ‘quality of life’ used as a text word or MeSH (medical sub-
ject headings) term. 
 Fig. 2. Publication trends regarding mental disorders (1981–2005). 
Medline search, ‘quality of life’ used as a text word or MeSH (med-
ical subject headings) term; depressive disorder, bipolar disorder, 
psychotic disorder, and anxiety disorder were used as MeSH 
terms. Search was restricted to major topic headings only. 
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depressive disorder and depressive symptoms were asso-
ciated with limitations in multiple domains of patient 
well-being and functioning. The functioning of depressed 
patients was comparable or even worse than that of pa-
tients with major chronic conditions. Furthermore, QoL 
assessment made it possible to compare the impact of dif-
ferent mental disorders  [11, 12] . This generic assessment 
of disorders becomes even more of an issue in the ex-
panding field of health economics, where budgetary al-
locations are based upon prioritization of illnesses. If ill-
nesses and their impact on society have to be compared, 
disease-specific scales are not suitable for making this 
comparison and generic scales are needed. The impor-
tance of this argument is highlighted by the findings of 
Gross et al.  [13] . These authors performed a cross-sec-
tional study, comparing estimates of disease-specific 
funding with different measures of the burden of disease. 
The number of disability-adjusted life-years (DALY) was 
strongly predictive of funding. The DALY combines in 1 
measure the time lived with disability and the time lost 
due to premature mortality. The combination of mental 
disorders being highly prevalent and associated with a 
substantial reduction in QoL could help to give patients 
with mental disorders a higher ranking on the scientific 
and financial agenda. 
 Finally, and also pertaining to the field of health eco-
nomics, is the use of QoL in cost-utility analysis. Cost-
utility analysis is the gold standard both for reporting 
cost-effectiveness and for informing policy decisions on 
the allocation of health care resources  [14] . It uses ‘qual-
ity-adjusted life-years’ as its unit of clinical effectiveness. 
‘Quality-adjusted life-years’ is a measure of a patient’s life 
expectancy, weighted by his/her health-related QoL. 
Again, this underscores the strategic importance of QoL 
measurements in the field of mental disorders and their 
treatment. 
 Quality of Life: What Is in a Name, What Is in a 
Measurement?  
 Health is defined as ‘a state of complete physical, men-
tal, and social well-being, and not merely the absence of 
disease’  [15] . Thereby, traditional outcome measures such 
as response and remission are necessary but not sufficient 
to declare that a treatment has been successful in restor-
ing health. QoL measurement encompasses the broader 
picture, i.e. what a person is capable of doing, access to 
resources and opportunities to use these abilities to pur-
sue interests, and a sense of well-being  [7] . This multidi-
mensional nature gives rise to lots of confusion in QoL 
measurement  [16] . After a critical evaluation of 75 papers 
in which QoL was measured, Gill and Feinstein  [17]  con-
cluded that many published QoL measurements seemed 
clinically inappropriate due to poor face validity: unclear 
conceptualization of underlying QoL concept, unclear 
definition of specific domains of measurement, and un-
clear justification of why a particular instrument has 
been chosen. 
 To counteract this problem and to anticipate the fur-
ther description of QoL measurement in recent antide-
pressant trials, a brief framework will be given of differ-
ent QoL measurements: general versus health-related 
versus disease-specific, objective versus subjective, a 
functionalist approach versus a needs-based approach, 
observer-rated versus self-rated, and a medical versus a 
mediational model. 
 General versus Health-Related versus Disease-Specific 
QoL  
 The World Health Organization defines QoL as indi-
viduals’ perceptions of their position in life in the context 
of culture and value systems in which they live and in re-
lation to their goals, expectations, standards, and con-
cerns. This ‘general quality of life’ concept is thereby af-
fected by the person’s physical health, psychological state, 
level of independence, social relationships, personal be-
liefs, and their relationship to salient features of their en-
vironment  [18] . ‘General quality of life’ can be distin-
guished from ‘health-related quality of life’, which focus-
es more on QoL directly influenced by the presence of 
emotional or physical illness, their prevention, and treat-
ment. Even more focused is a ‘disease-specific quality of 
life’ assessment, tailored to a specific disorder and its 
treatment  [7, 19] . 
 By being more specific, QoL measurements may be-
come more sensitive to change. However, this could be at 
the cost of losing some of the initial purposes of QoL 
measurement, e.g. capturing the broader psychological 
and sociological dimensions of life, and making compar-
isons between different clinical conditions. Finally, the 
more disease-specific a QoL scale becomes, the higher 
the risk of overlap with symptom scales  [16] . 
 Objective versus Subjective QoL  
 Objective QoL is defined by what a person is capable 
of doing (functional status), access to resources, and the 
opportunities to use these abilities to pursue interests 
(living conditions). A sense of well-being and satisfaction 
are thus referred to as subjective QoL. Functional status 
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and living conditions are also called the sociological di-
mensions of QoL, well-being and satisfaction are the psy-
chological dimensions. Objective and subjective QoL are 
complementary aspects of an individual’s life situation, 
in which different life domains are to be distinguished: 
general and mental health, family, social relations, finan-
cial status, housing situation, leisure activities, and per-
sonal safety  [7, 20] . 
 Functionalist Approach versus Needs-Based Approach 
 In a functionalist approach, QoL is seen as the ability 
to perform roles that are considered normal for people in 
western societies. The assumption is made that there is 
an optimal level of functioning to which all human be-
ings should aspire. Health-related QoL is then defined as 
the impact of treatment and disease on disability and dai-
ly functioning. Within a needs-based approach, life gains 
its quality from the ability and capacity of individuals to 
satisfy their needs, either inborn or learned during so-
cialization processes. These needs may be physical, emo-
tional, or social  [8, 21] . A needs-based approach takes into 
consideration that people may be satisfied with life (in-
ternal QoL standard), without reaching an optimal level 
of functioning (external QoL standard). 
 Observer-Rated versus Self-Rated QoL  
 QoL assessment has focused mainly on the subjective 
perspective of the patient: ‘QoL, unlike beauty, doesn’t 
rest in the eye of the beholder, but is an attribute of the 
beholdee or patient’  [17] . Most QoL assessments have 
thereby been developed as self-rating scales, or interviews 
to directly pick up a patient’s point of view. This adoption 
of subjective QoL assessment in psychiatry is not without 
critique: the main critique being that subjective well-be-
ing (an emotional appraisal) and satisfaction (a cognitive 
appraisal) are both at risk of just reflecting altered psy-
chological states: influence of mood states, hallucinations 
and delusions, lack of insight, and intellectual or cogni-
tive deficits. Therefore, some authors have argued for the 
use of different perspectives in QoL assessments: in an 
ideal situation this could be the patient, a family member 
or friend, and a professional. These viewpoints will pos-
sibly contradict each other, but have to be seen as funda-
mentally complementary  [3] . 
 Medical versus Mediational Model  
 Despite the growing interest in QoL, little theory has 
been generated and few of the empirical findings have 
been placed in a theoretical framework. Without such a 
framework, findings on QoL in patients with mental dis-
orders are sometimes difficult to understand, especially 
the only moderate correlation between the objective in-
dicators and subjective measures  [22] . For this, a media-
tional model of QoL has been developed. An appraisal 
process is put forward mediating between objective indi-
ces (e.g. living conditions, side effects, and symptoms) 
and perceived quality of life (e.g. expectations, aspira-
tions, and comparison standards). This appraisal process 
is influenced by self-related constructs like self-efficacy, 
self-esteem, and perceived control. These self-related 
constructs are further influenced by clinical and person-
al characteristics  [22, 23] . This complex appraisal process 
could explain why patients with a similar severity of side 
effects and symptoms may differ in their QoL. The me-
diational model thereby expands the former medical 
model, in which QoL was just the balance between side 
effects and symptoms. 
 QoL in Antidepressant Trials: A Focus on Duloxetine 
and Escitalopram  
 A closer look will now be taken at how the former QoL 
issues are translated in papers reporting on antidepres-
sant trials (treatment of major depressive disorder in 
adults). For this purpose, a Medline search was performed 
for 2 recently approved antidepressants, duloxetine and 
escitalopram  [24, 25] : ‘depressive disorder’ (MeSH term, 
restricted to major topic headings only) and ‘duloxetine’; 
‘depressive disorder’ (MeSH term, restricted to major 
topic headings only) and ‘escitalopram’. A selection was 
made for ‘randomized controlled trial’ as type of article. 
Medline was assessed on June 27, 2007. Selected papers 
were checked on the use of QoL measurements and the 
representation of this throughout the text: QoL measure-
ments that were used, mentioned and described in the 
different sections of the paper.
 In the duloxetine Medline search, 22 papers were ini-
tially found. After reading the abstracts, a first selection 
of 16 papers was made. Papers were excluded for different 
reasons: 2 methodological papers exploring different ef-
ficacy assessments (effect size, number needed to treat), 
2 papers with fibromyalgia as the main topic, 1 paper re-
porting on relationships between outcomes and episode 
characteristics, and 1 paper reporting on an open-label 
trial. QoL measurements were used in 10 out of 16 papers, 
which became the final selection for further analysis  [26–
35] . Seven papers were reports of original trial data  [26–
28, 30, 31, 34, 35] , and 3 papers were post hoc analyses  [29, 
32, 33] . QoL assessment was briefly mentioned in the ab-
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stracts of 7 papers  [28–32, 34, 35] . The Quality of Life in 
Depression Scale (QLDS) was used in 8 papers  [27–29, 
31–35] , and the Sheehan Disability Scale in 4 papers  [26–
28, 30] . For all but 2 of the papers, the only mention of the 
QoL instrument in the methods section was its name and 
the time of assessment; in the paper of Fava et al.  [27] , this 
was preceded by: ‘health outcomes were evaluated using 
the …’. In the paper of Perahia et al.  [28] , the QLDS and 
Sheehan Disability Scale were used to ‘measure disrup-
tion of the patient’s work, social and home life by their 
symptoms’. In none of the papers was it explained why a 
particular QoL scale was chosen. In 8 papers, the QoL as-
sessment was mentioned in the results section  [27–32, 34, 
35] . In all but 1 paper  [32] , this mention was a very brief 
description of the results in words and/or a table. A sig-
nificantly greater improvement in QoL of patients treated 
with duloxetine versus placebo was shown in most stud-
ies. No differential effect on QoL was found when com-
pared with paroxetine. In the paper of Fava et al.  [32] , this 
information was supplemented with correlations be-
tween improvements in QoL and other measurements, 
e.g. the correlation coefficient of QLDS score with the 17-
Item Hamilton Rating Scale for Depression (HAM-D-17) 
Maier subscale was 0.71 (p  ! 0.001), the correlation coef-
ficient of QLDS score with psychic anxiety (HAM-D-17 
item 10) was 0.53 (p  ! 0.001). Overall, QoL findings were 
discussed in 7 out of 10 papers  [28, 29, 31–35] . In line with 
the results sections, these discussions were rather con-
cise. In the papers of Fava et al.  [27] and Detke et al.  [34, 
35] , this was done more extensively, i.e. additional infor-
mation was provided on the potential beneficial effect of 
duloxetine on QoL by acting on emotional and physical/
painful symptoms. 
 In the escitalopram Medline search, 24 papers were 
initially found. After reading all the abstracts, a first se-
lection of 19 papers was made. Papers were excluded for 
different reasons: 1 paper on the use of escitalopram in 
paediatric depression, 1 paper on the use of repetitive 
transcranial magnetic stimulation, 2 papers reporting on 
an open-label trial, and 1 paper already withheld in the 
duloxetine search. QoL measurements were used in 6 out 
of 19 papers, which became the final selection used for 
further analysis  [36–41] . Four papers were reports of 
original trial data  [36, 38, 40, 41] , 2 papers were post hoc 
analyses  [37, 39] . In 4 of these papers, QoL assessment was 
briefly mentioned in the abstract  [37, 39–41] . The Qual-
ity of Life Enjoyment and Satisfaction Questionnaire
(Q-LES-Q) was used in 5 papers  [36–40] . In 2 papers  [39, 
40] , it was explicitly mentioned that a 16-item version was 
used; in the other papers, a short version could be as-
sumed to have been used, but this was not explicitly men-
tioned. The EuroQol 5D (EQ-5D) dimensions were used 
in 2 papers  [37, 41] . The QLDS was also used in 2 papers 
 [37, 41] . In 4 papers, the Centre for Epidemiological Stud-
ies Depression Scale (CES-D) was used  [36–38, 40] , and 
in 3 papers it was referred to as an assessment of patient 
functioning/QoL  [37, 38, 40] . Papers differed in how they 
mentioned QoL measurement in their methods section. 
In the paper of Ventura et al.  [36] only the name (Q-LES-
Q) and timing of assessment was described. In the papers 
of Bielski et al.  [38] , Bech et al.  [39] and Burke et al.  [40] , 
this was supplemented with some references to patient or 
social functioning. In the papers of Montgomery and An-
dersen  [37] and Fernandez et al.  [41] , a rather extensive 
description of the QoL measurements was given: e.g. ‘EQ-
5D determines health states on five dimensions: mobility, 
self-care, usual activities, pain/discomfort and anxiety 
depression’ and ‘the 34-item QLDS measures the ability 
and capacity of individuals to satisfy their needs.’ In none 
of the papers was it explained why a particular QoL scale 
was chosen. All papers reported on QoL in their results 
sections, and when compared with the duloxetine papers 
this was done more extensively. The main results were a 
significantly greater improvement in QoL of patients 
treated with escitalopram versus placebo, no differential 
effect when compared to sertraline or venlafaxine, supe-
riority of 20 mg escitalopram on the Q-LES-Q to both 10 
mg escitalopram and 40 mg citalopram. No further anal-
yses (e.g. correlations between improvement in QoL and 
other measurements) were made. QoL findings were dis-
cussed in 4 out of 6 papers  [38–41] . In the papers of Fer-
nandez et al.  [41] , Bech et al.  [39] and Burke et al.  [40] , this 
was done more extensively. In particular, Bech et al.  [39] 
made some theoretical considerations on lower effect siz-
es with Q-LES-Q (than those obtained with HAM-D and 
MADRS), and how this could be explained by QoL need-
ing more time to reach remission. 
 Discussion 
 As shown in this analysis of randomized controlled tri-
als of duloxetine and escitalopram, QoL measurement is 
still an active area of interest in the field of major depres-
sive disorder, being used in 63 and 32% of papers on du-
loxetine (10/16) and escitalopram (6/19), respectively. This 
interest is in line with the broader popularity of QoL in 
medicine and psychiatry. QoL measurement is no longer 
limited to open-label or post-marketing trials  [42] , but is 
implemented in the earlier phases of drug development. 
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 When looking at the use of QoL measurement in these 
trials from a historical perspective, it is clear that we have 
gone a long way from the initial developments: monitor-
ing the long-term care of chronically ill people, and an 
alternative outcome measure for patients with severe 
mental disorders in the aftermath of deinstitutionaliza-
tion and the psychopharmacology revolution. In these re-
cent antidepressant trials, QoL measurement was used in 
a selected population of depressed patients during a rela-
tively brief time frame. 
 The critique of Gill and Feinstein  [17] is still painfully 
up to date: an unclear conceptualization of the underly-
ing QoL concept, unclear definition of specific domains 
of measurement, and unclear justification of why a par-
ticular instrument has been chosen.  Table 1 gives an 
overview of the different QoL instruments that are used 
 [43–47] . None of the papers mention why a particular 
QoL scale has been chosen, or refer to a specific QoL con-
cept. A subjective perspective is prevailing, i.e. all scales 
being self-rated. Although a needs-based approach is re-
flected in the use of scales like the QLDS and Q-LES-Q, 
a more functionalist approach is reflected in the limited 
description of the scales throughout the papers. In the 
papers of Montgomery et al.  [37] , Bielski et al.  [38] and 
Burke et al.  [40] , the CES-D is mentioned as a QoL assess-
ment or an assessment of ‘patient functioning’. However, 
the CES-D is a self-rating inventory of depressive symp-
toms, not an assessment of QoL or functioning. For these 
authors, QoL measurement is reduced to a subjective 
view of symptoms. 
 Describing the QoL measurement throughout the pa-
pers was mostly done in a concise way. In patients with 
depressive disorder and who were treated with antide-
pressants, QoL measurement has been demonstrated to 
be sensitive to change. As shown in the paper of Fava et 
al.  [32] , improvement in QoL correlates highly with im-
provements in depressive symptoms. This confirms the 
results of earlier reviews on this topic: improvements 
shown in QoL measures during the acute and long-term 
treatment of depression  [48, 49] , and high concurrent va-
lidity when compared to standard depression rating 
scales  [50] . 
 Only limited additional data have been generated re-
garding the discriminating, teleological, or predictive va-
lidity of QoL measurement, for which some preliminary 
evidence exists  [1, 42, 48, 50, 51] . First, QoL measurement 
can capture subtle differences between treatment modal-
ities, not shown in depression rating scales (discriminat-
ing validity). Second, QoL measurement can be a better 
endpoint of treatment evaluation than symptom scales 
(e.g. by offering normal population values to which pa-
tients values could be compared; teleological validity). 
Third, QoL measurement can have some predictive va-
lidity, e.g. prediction of non-compliance or recurrence. 
Only in the paper of Bech et al.  [39] was a comment made 
on generally lower effect sizes with Q-LES-Q than those 
obtained with standard depression rating scales. These 
results are similar to those of a recent paper of Endicott 
et al.  [52] , i.e. lower effect sizes of quetiapine in the treat-
ment of bipolar depression when measured with the
Q-LES-Q (vs. Montgomery-Asberg Depression Rating 
Scale). This could point to a slower remission rate in 
terms of QoL (versus depressive symptoms). 
Table 1. QoL instruments used in randomized controlled trials of duloxetine and escitalopram in major depressive disorder
Sheehan Disability
Scale [43]
3-item inventory to assess the degree to which symptoms have
disrupted patient’s work, social life, and family life
health-related, objective, self-rated,  
functionalist approach
QLDS [44] 34-item inventory to assess the impact of depressive symptoms
on QoL (domestic activities, interpersonal relationships, social life, 
cognition, personal hygiene, leisure activities, relaxation)
disease-specific, subjective, self-rated,  
many items overlapping with depres-
sive symptoms, needs-based approach
Q-LES-Q [45] 93-item inventory to assess the degree of enjoyment and satisfaction 
in different life domains (physical health, work, school, household 
duties, subjective feelings, leisure activities, social relationships,
general activities); a 15-item short form is used in the included trials
health-related, subjective, self-rated,  
needs-based approach
EuroQol 5D [46] 5-item inventory to assess problems in 5 different life domains
(mobility, self-care, usual activities, pain/discomfort, anxiety/
depression) + visual analogue of health status
health-related, subjective, self-rated
CES-D [47] 20-item inventory to assess severity of depressive symptoms depression rating scale, self-rated
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 Therefore, the added value of QoL measurement in re-
cent antidepressant trials is unclear: additional benefit 
for the patient seems limited and additional information 
for the QoL literature almost non-existent. In view of 
QoL being a topic with a lot of potential and the efforts 
that have been made by researchers, clinicians, and pa-
tients in making these trials possible, QoL measurement 
in recent antidepressant trials is surely a story of missed 
opportunities. Indeed, it is the opinion of the authors that 
QoL measurement should be included in future antide-
pressant trials. QoL scales should be well chosen from an 
underlying theory, and have a clearly defined purpose. 
Questions of concurrent, discriminating, teleological, 
and predictive validity should be answered in primary or 
secondary data analysis. QoL measurement is in line with 
the differential assessment of treatment outcome: not be-
ing a unitary concept, but covering core depressive symp-
toms, social and cognitive functioning, and well-being 
 [51] . This differential assessment is then in line with stag-
ing and sequential treatment as described by Fava et al. 
 [53–56] and Hetrick et al.  [57] . When selecting a QoL 
scale, the time course of the depressive disorder should 
be taken into account: different phases call for different 
assessment and treatment  [58] . Depression rating scales 
and disease-specific QoL scales could be more useful
in the earlier phases of the depressive disorder, while 
health-related and general QoL scales (with population 
norms) could be preferential in the later phases. This lat-
ter assessment could be useful in the detection of both 
residual and prodromal symptoms targeted by tailored 
therapy.
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